Biolegend, 311404, FITC anti-human HLA-A,B,C Antibody, 100tests

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8 + T cells. They play an important role in cell-mediated immune responses and tumor surveillance.
100tests
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: African Green, Baboon, Cat, Cow, Chimpanzee
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)
Application Notes: Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Darrow TL, et al. 1989. J. Immunol. 142:3329. Stern P, et al. 1987. J. Immunol. 138:1088. Tran TM, et al. 2001. Immunogenetics 53:440. Barbatis C, et al. 1981. Gut 22:985. Ayyoub M, et al. 2004. Cancer Immunity 4:7. DeFelice M, et al. 1990. Cell. Immunol. 126:420. Fayen J, et al. 1998. Int. Immunol. 10:1347. Turco MC, et al. 1988. J. Immunol. 141:2275. Geppert TD, et al. 1989. J. Immunol. 142:3763. Wooden SL, et al. 2005. J. Immunol. 175:1383. Nagano M, et al. 2007. Blood 110:151. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope) Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations: Yumoto K, et al. 2023. Transl Oncol. 31:101642. PubMed Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed Mirlashari MR, et al. 2021. Transfusion. 61:1222. PubMed Weingarten-Gabbay S, et al. 2022. STAR Protoc. 3:101910. PubMed Di Matteo S, et al. 2022. Cancers (Basel). 15: . PubMed Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed Abreu SC, et al. 2020. Am J Physiol Lung Cell Mol Physiol. 319:L908. PubMed Robinson A, et al. 2017. Stem Cell Res Ther. 10.1186/s13287-017-0540-3. PubMed Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed Hess NJ, et al. 2020. J Immunol. 205:272. PubMed Wu Y, et al. 2021. Nat Biomed Eng. 5:1336. PubMed McDaid WJ, et al. 2021. Nanoscale. 13:15010. PubMed Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed Tallerico R, et al. 2017. Oncoimmunology. 6:e1284718. PubMed Sharma R, et al. 2021. Nat Commun. 12:472. PubMed Robinson A, et al. 2015. PLoS One. 10: 0139023. PubMed Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed Yumoto K, et al. 2016. Sci Rep. 6:36520. PubMed OConnor RA, et al. 2021. OncoImmunology. 10(1):1940675. PubMed Liu X, et al. 2017. International Immunopharmacology. 10.1016/j.intimp.2017.04.012. PubMed Wei C, et al. 2012. J Allergy Clin Immunol. 129:1562. PubMed Chen X, et al. 2015. Mol Immunol. 65:34. PubMed Meng J, et al. 2010. Clin Vaccine Immunol. 1.325694444. PubMed Yin Z, et al. 2012. J Immunol. 189:2735. PubMed Tangtanatakul P, et al. 2017. Sci Rep. 7:14517. PubMed Takahashi A, et al. 2021. Front Oncol. 11:707473. PubMed Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed Ng S, et al. 2022. Sci Rep. 12:14087. PubMed Tallerico R, et al. 2013. J Immunol. 190:2381. PubMed Chew GL et al. 2019. Dev Cell. 50(5):658-671 . PubMed Song L, et al. 2021. J Invest Dermatol. 141:903. PubMed Qi YA, et al. 2021. Mol Cell Proteomics. 20:100136. PubMed Mirlashari MR, et al. 2021. Proteomics Clin Appl. 15:e2100022. PubMed Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed Ritter C, et al. 2017. Scientific Reports. 10.1038/s41598-017-02608-0. PubMed Nosaka K, et al. 2021. Anticancer Res. 41:4741. PubMed Wang H, et al. 2022. J Cancer. 13:2126. PubMed
RRID: AB_314872 (BioLegend Cat. No. 311403) AB_314873 (BioLegend Cat. No. 311404)
Structure: Ig superfamily
Distribution: All nucleated cells
Function: Antigen presentation
Ligand/Receptor: CD3/TCR, CD8
Biology Area: Immunology, Innate Immunity
Molecular Family: MHC Antigens
Antigen References: 1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.
Gene ID: 3105
UniProt: View information about HLA-A on UniProt.org
Clone: W6/32
Regulatory Status: RUO
Other Names: Major Histocompatibility Class I, MHC class I
Isotype: Mouse IgG2a, κ